Ascletis Pharma Inc. (SEHK: 1672)
Health Care · Biotechnology · HK
HK$6.96
-14.23% today · -29.5% 1Y
Ascletis Pharma Inc. (SEHK: 1672) operates in the Biotechnology industry within the Health Care sector. The company is valued at $936.85M and employs 202 people.
Over the last twelve months the share price has lost 29.5%, trading between 6.92 and 19.86.
Tweenvest scores Ascletis Pharma Inc. across four factors: quality 41/100, value 42/100, growth 0/100. Its strongest factor is value.
1672 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $936.85M
- Revenue (TTM)
- $139.41K
- P/E
- —
- EPS
- -0.59
- Dividend yield
- —
- Beta (5Y)
- 0.43
- 52-week high
- HK$19.86
- 52-week low
- HK$6.92
- Avg volume (3M)
- —
- Shares outstanding
- 1.06B
- Employees
- 202
- Next earnings
- —
About Ascletis Pharma Inc.
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
- ISIN
- KYG0520K1094
- Founded
- 2013
- Listed since
- Aug 1, 2018
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Jiangsu Aidea Pharmaceutical Group Co., Ltd.SHSE: 688488 | $989.43M | CN¥15.75 | -5.29% |
| Basilea Pharmaceutica AGSWX: BSLN | $979.21M | CHF65.50 | -1.95% |
| Shanghai Haohai Biological Technology Co., Ltd.SEHK: 6826 | $943.26M | HK$16.11 | +0.25% |
| Kura Oncology, Inc.NasdaqGS: KURA | $942.98M | $10.60 | +0.76% |
| Ingenia Therapeutics Inc.KOSDAQ: A950260 | $932.34M | ₩25,350.00 | -12.13% |
| LongBio Pharma (Suzhou) Co., Ltd.SEHK: 1779 | $926.52M | HK$98.00 | -3.64% |
| MoonLake ImmunotherapeuticsNasdaqCM: MLTX | $920.85M | $10.82 | +2.27% |
| Rigel Pharmaceuticals, Inc.NasdaqGS: RIGL | $916.81M | $49.08 | +0.74% |
Figures last refreshed Oct 11, 2026.